MedTrace Logo

Safety and Efficacy of KSVCBD Injection in Autoimmune Diseases

NCT07613411 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-29

No results posted yet for this study

Summary

KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This single-arm, open-label, early exploratory clinical study is designed to evaluate the safety and preliminary efficacy of KSVCBD injection in patients with Autoimmune Diseases.

Conditions

Interventions

DRUG

KSVCBD injection

KSVCBD injection is an in vivo CAR-T therapy targeting CD19/BCMA and is administered by IV infusion.

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Principal Investigators

  • Jian Zhu · Rheumatology Department of Chinese PLA General Hospital

  • Weidong Han · Biotherapeutic Department of Chinese PLA General Hospital

  • Yang Liu · Biotherapeutic Department of Chinese PLA General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2028-12-31
Completion
2029-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07613411 on ClinicalTrials.gov